InvestorsHub Logo
Followers 5
Posts 229
Boards Moderated 0
Alias Born 08/16/2018

Re: None

Friday, 08/16/2019 12:51:46 PM

Friday, August 16, 2019 12:51:46 PM

Post# of 118380


Zander and Regen are under common control. David Koos serves as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Todd S. Caven serves as CFO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos and Caven also serve as Directors of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of NR2F6 intellectual property licensed to Zander by KCL Therapeutics, Inc. for veterinary applications. KCL Therapeutics Inc. is a majority owned subsidiary of Regen.